Matinas BioPharma mulls wind-down as antifungal therapy deal falls through
The company has axed 80% of its staff and is considering a wind-down after the out-licencing deal of its lead antifungal was terminated.
The company has axed 80% of its staff and is considering a wind-down after the out-licencing deal of its lead antifungal was terminated.
What's Your Reaction?
